Company Analysis
Sign in

Rigel Pharmaceuticals, Inc. (RIGL)

Nasdaq: RIGL · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2000
Full chart Alerts Compare
Grade6.4
◀ Past 5.0● Present 7.6▶ Future 6.3
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

493 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Rigel Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
493
490 utility, 3 reissue, 1976 to Dec 31, 2025
Granted in 2025
9
Against 7 in 2024 and 7 in 2023
Applications published
486
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals29
Organic fine chemistry27
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Rigel Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
493 granted
392 published
Rigel Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
94 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,459,941Tricyclic IRAK inhibitorsPharmaceuticalsRigel Pharmaceuticals, Inc.
Oct 21, 202512,448,366Solid forms of pralsetinibOrganic fine chemistryRigel Pharmaceuticals, Inc.
Oct 14, 202512,441,723Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulationsOrganic fine chemistryRigel Pharmaceuticals, Inc.
Aug 12, 202512,384,775Pyrimid-2-yl-pyrazole compounds as IRAK inhibitorsOrganic fine chemistryRigel Pharmaceuticals, Inc.
Jul 15, 202512,357,623Method for treating a disease or condition using a pyrazole compound or formulation thereofPharmaceuticalsRigel Pharmaceuticals, Inc.
Jun 17, 202512,331,036Heterocyclic RIP1 kinase inhibitorsOrganic fine chemistryRigel Pharmaceuticals, Inc.
May 13, 202512,297,202RIP1K inhibitorsOrganic fine chemistryRigel Pharmaceuticals, Inc.
Apr 1, 202512,263,180Method for treatment of COVID-19-associated conditionsPharmaceuticalsRigel Pharmaceuticals, Inc.
Feb 18, 202512,227,508TGF-β inhibitorsPharmaceuticalsRigel Pharmaceuticals, Inc.
Dec 3, 202412,156,880Heterocyclic RIP1 kinase inhibitorsPharmaceuticalsRigel Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0333408PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORSOrganic fine chemistryRigel Pharmaceuticals, Inc.
Oct 23, 20252025/0326778PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDSPharmaceuticalsRigel Pharmaceuticals, Inc.
Sep 4, 20252025/0275956TREATMENT OF CNS TUMORS WITH OLUTASIDENIB AND TEMOZOLOMIDEPharmaceuticalsRigel Pharmaceuticals, Inc.
Mar 20, 20252025/0092057HETEROCYCLIC RIP1 INHIBITORY COMPOUNDSOrganic fine chemistryRigel Pharmaceuticals, Inc.
Feb 6, 20252025/0041297RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATIONPharmaceuticalsRigel Pharmaceuticals, Inc.
Jan 30, 20252025/0034100RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAMEOrganic fine chemistryRigel Pharmaceuticals, Inc.
Jan 16, 20252025/0019372CRYSTALLINE FORMS OF A RIPK1 INHIBITORPharmaceuticalsRigel Pharmaceuticals, Inc.
Jan 2, 20252025/0000872FORMULATIONS AND DOSING REGIMENS FOR RIP1 KINASE INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASESPharmaceuticalsRigel Pharmaceuticals, Inc.
Dec 19, 20242024/0417386INHIBITORS OF RETOrganic fine chemistryRigel Pharmaceuticals, Inc.
Nov 21, 20242024/0382470Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory VirusPharmaceuticalsRigel Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 6 · Pharmaceuticals 6.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RIGL · research, not advice